Immunic (IMUX) Q2 Loss Widens 25%
(NASDAQ:IMUX), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by meaningful clinical progress for its lead product candidate but also persistent financial challenges. There was no revenue reported, consistent with its pre-commercial status. Overall, the period reflected operational headway in drug development but a continued need for capital to fund ongoing trials.
Source: Analyst estimates for the quarter provided by FactSet.
Immunic is a clinical-stage biotechnology company. It is primarily developing therapies for chronic inflammatory and autoimmune diseases. Its most advanced program is focused on multiple sclerosis, a disabling neurological condition that affects millions worldwide.
Source Fool.com
Immunic Inc. Aktie
Durchaus positiv bewertet unsere Community derzeit Immunic Inc. mit 20 Buy-Einschätzungen und 1 Sell-Einschätzungen.
Mit einem Kursziel von 8 € für Immunic Inc. zeigt sich ein beachtliches Wachstumspotenzial gegenüber dem aktuellen Kurs von 0.8 €.
